Ablynx And Merck Enter Immune Checkpoint Blocker Nanobody Pact
This article was originally published in The Pink Sheet Daily
Ablynx and Merck & Co have expanded their ties by creating a new research alliance aimed at developing predefined nanobody candidates, including bi- and tri-specifics, directed at immune checkpoint modulators involved in cancer.
You may also be interested in...
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.